公开(公告)号：US20210402083A1

公开(公告)日：2021-12-30

申请号：US17386659

申请日：2021-07-28

Applicant: AMGEN INC.

Inventor： Scott R. Gibson ,  Sheldon B. Moberg ,  Basel Hasan Taha ,  Margaux Frances Boyaval ,  Mark A. Destefano ,  Lawton Laurence ,  John C. Love ,  Ian B. Hanson ,  Paul F. Bente, IV ,  Matthew J. Clemente ,  Antonio Ubach ,  Rajan Ramaswamy ,  Daniel S. Codd ,  Scott Beaver ,  Kevin L. Bokelman ,  Ian P. Dardani ,  Sean M. O'connor ,  Danielle Feldman

IPC: A61M5/145 ,  A61M5/142 ,  A61M5/158

Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.

公开(公告)号：US11266777B2

公开(公告)日：2022-03-08

申请号：US16071873

申请日：2017-02-13

Applicant: AMGEN INC.

Inventor： Scott R. Gibson ,  Sheldon B. Moberg ,  Basel Hasan Taha ,  Margaux Frances Boyaval ,  Mark A. Destefano ,  John C. Love ,  Ian B. Hanson ,  Paul F. Bente, IV ,  Matthew J. Clemente ,  Rajan Ramaswamy ,  Daniel S. Codd ,  Scott Beaver ,  Kevin L. Bokelman ,  Sean M. O'connor ,  Robert Decker ,  Gautam N. Shetty ,  Ryan M. Agard ,  Nicholas J. Ciccarelli ,  Daniel Davenport

IPC: A61M5/142 ,  A61M5/145 ,  A61M5/315 ,  A61M5/24

Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.

公开(公告)号：US11129936B2

公开(公告)日：2021-09-28

申请号：US16089685

申请日：2017-04-07

Applicant: AMGEN INC.

Inventor： Scott R. Gibson ,  Sheldon B. Moberg ,  Basel Hasan Taha ,  Margaux Frances Boyaval ,  Mark A. Destefano ,  Lawton Laurence ,  John C. Love ,  Ian B. Hanson ,  Paul F. Bente, IV ,  Matthew J. Clemente ,  Antonio Ubach ,  Rajan Ramaswamy ,  Daniel S. Codd ,  Scott Beaver ,  Kevin L. Bokelman ,  Ian P. Dardani ,  Sean M. O'connor ,  Danielle Feldman

IPC: A61M5/145 ,  A61M5/142 ,  A61M5/158

Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device includes a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector defines a sterile fluid flowpath between the container and the insertion mechanism. A cannula initially disposed about the needle is included.

公开(公告)号：US12201809B2

公开(公告)日：2025-01-21

申请号：US17386659

申请日：2021-07-28

Applicant: AMGEN INC.

Inventor： Scott R. Gibson ,  Sheldon B. Moberg ,  Basel Hasan Taha ,  Margaux Frances Boyaval ,  Mark A. Destefano ,  Lawton Laurence ,  John C. Love ,  Ian B. Hanson ,  Paul F. Bente, IV ,  Matthew J. Clemente ,  Antonio Ubach ,  Rajan Ramaswamy ,  Daniel S. Codd ,  Scott Beaver ,  Kevin L. Bokelman ,  Ian P. Dardani ,  Sean M. O'connor ,  Danielle Feldman

IPC: A61M5/142 ,  A61M5/145 ,  A61M5/158 ,  A61M5/168

Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.

公开(公告)号：US20220218900A1

公开(公告)日：2022-07-14

申请号：US17688578

申请日：2022-03-07

Applicant: AMGEN INC.

Inventor： Scott R. Gibson ,  Sheldon B, Moberg ,  Basel Hasan Taha ,  Margaux Frances Boyaval ,  Mark A. Destefano ,  John C. Love ,  Ian B. Hanson ,  Paul F. Bente, IV ,  Matthew J. Clemente ,  Rajan Ramaswamy ,  Daniel S. Codd ,  Scott Beaver ,  Kevin L. Bokelman ,  Sean M. O'connor ,  Robert Decker ,  Gautam N. Shetty ,  Ryan M. Agard ,  Nicholas J. Ciccarelli ,  Daniel Davenport

IPC: A61M5/142 ,  A61M5/145 ,  A61M5/315

Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.

公开(公告)号：US20200316291A1

公开(公告)日：2020-10-08

申请号：US16089685

申请日：2017-04-07

Applicant: AMGEN INC.

Inventor： Scott Robert Gibson ,  Sheldon B. Moberg ,  Basel Hasan Taha ,  Margaux Frances Boyaval ,  Mark A. Destefano ,  Lawton Laurence ,  John C. Love ,  Ian B. Hanson ,  Paul F. Bente, IV ,  Matthew J. Clemente ,  Antonio Ubach ,  Rajan Ramaswamy ,  Daniel S. Codd ,  Scott Beaver ,  Kevin L. Bokelman ,  Ian P. Dardani ,  Sean M. O'connor ,  Danielle Feldman

IPC: A61M5/145 ,  A61M5/158 ,  A61M5/142

Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device includes a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector defines a sterile fluid flowpath between the container and the insertion mechanism. A cannula initially disposed about the needle is included.